An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause.

Autor: Eichler S; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany. Electronic address: susann.eichler@drwolffgroup.com., Panz M; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany., Harder A; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany., Masur C; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany., Häuser M; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany., Wiesche ESZ; Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany.
Jazyk: angličtina
Zdroj: Maturitas [Maturitas] 2024 Jul; Vol. 185, pp. 107978. Date of Electronic Publication: 2024 Mar 29.
DOI: 10.1016/j.maturitas.2024.107978
Abstrakt: Objectives: The efficacy and tolerability of a non-hormonal pessary (that forms an oil-in-water emollient with the vaginal fluid) were assessed for the treatment of symptoms of vaginal dryness associated with menopause.
Study Design: Seventy-nine postmenopausal women (mean age 60.8 ± 6.5 years) with mild to moderate symptoms of vaginal dryness (including dyspareunia) were enrolled in this open-label, prospective, post-market clinical follow-up trial, conducted in 2022 by one research center in Germany. The investigational pessary was applied for the first 7 days once daily and the subsequent 31 days twice a week, at bedtime. A treatment-free period of 6 days completed the trial.
Main Outcome Measures: During the trial, participants filled out questionnaires that enabled the calculation of a total severity score for subjective symptoms of atrophy-related vaginal dryness and impairment of daily as well as sexual life. Furthermore, vaginal health index and safety were studied.
Results: A rapid and significant reduction in the severity scores for symptoms was observed over the 38-day course of treatment and beyond. Quality of life assessed by DIVA (day-to-day impact of vaginal aging) questionnaire, dyspareunia and vaginal health index also clearly improved. The tolerability was mainly rated as "good to very good" by the investigator and 94.9 % of participants. The vast majority were very satisfied with the simple and pleasant handling. No serious adverse events occurred.
Conclusion: Overall, the presented data suggest that the investigated non-hormonal pessary is an effective and well tolerated treatment option for vaginal symptoms associated with dryness, thus improving quality of life for women, even those who are sexually active.
Clinicaltrials: gov identifier NCT05211505.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: all authors are employees of Dr. August Wolff GmbH & Co. KG Arzneimittel, 33611 Bielefeld, Germany.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: